Alocril - General Information
A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
Pharmacology of Alocril
Alocril is a anti-inflammatory agent and can be administered directly to the bronchial mucosa. It has significant inhibitory effect on allergen-induced early and late asthmatic reactions and on bronchial hyperresponsiveness.
Alocril for patients
Patients should be told that:
Tilade must be taken regularly to achieve benefit, even during symptom-free periods.
Tilade is not meant to relieve acute asthma symptoms. If symptoms do not improve or the patient's condition worsens, the patient should not increase the dosage but should notify the physician immediately.
They should not decrease the dose without the physician's knowledge. The recommended dose should not be exceeded.
The full therapeutic effect of Tilade may not be obtained for 1 week or longer after initiating treatment.
Because the therapeutic effect depends upon local delivery to the lungs, it is essential that patients be properly instructed in the correct method of use.
An illustrated leaflet for the patient is included in each Tilade Inhaler pack.
In clinical studies, Tilade has been co-administered with other anti-asthma medications, including inhaled and oral bronchodilators, and inhaled corticosteroids, with no evidence of increased frequency of adverse events or laboratory abnormalities. No formal drug-drug interaction studies, however, have been conducted.
Tilade Inhaler is contraindicated in patients who have shown hypersensitivity to nedocromil sodium or other ingredients in this preparation.
Additional information about Alocril
Alocril Indication: For the treatment of mild to moderate asthma
Mechanism Of Action: Alocril has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Alocril inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-geneñrelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Alocril does not posess any bronchodilator, antihistamine, or corticosteroid activity.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Nedocromil
Synonyms: Not Available
Drug Category: Anti-Allergic Agents; Anti-Asthmatic Agents; Anti-inflammatory Agents
Drug Type: Small Molecule; Approved
Other Brand Names containing Nedocromil: Alocril; Nedocromil [USAN-BAN-INN]; Nedocromilo [Spanish]; Nedocromilum [Latin]; Tilade;
Toxicity (Overdose): Side effects include headache, nasal congestion, ocular burning, irritation and stinging, unpleasant taste, cough, difficulty breathing, noisy breathing, shortness of breath, tightness in chest, wheezing, conjunctivitis, blurred vision, change in color vision, difficulty seeing at night, increased sensitivity of eyes to sunlight.
Protein Binding: approximately 89% protein bound in human plasma over a concentration range of 0.5 to 50 µg/mL
Biotransformation: Nedocromil is not metabolized after IV administration and is excreted unchanged.
Half Life: ~3.3 hours
Dosage Forms of Alocril: Liquid Ophthalmic
Chemical IUPAC Name: 9-ethyl-4,6-dioxo-10-propylpyrano[5,6-g]quinoline-2,8-dicarboxylic acid
Chemical Formula: C19H17NO7
Nedocromil on Wikipedia: http://en.wikipedia.org/wiki/Nedocromil
Organisms Affected: Humans and other mammals